Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test

Rezolute's stock plummeted 87% after its lead drug candidate, ersodetug, failed to meet its primary and key secondary endpoints in a Phase 3 study for congenital hyperinsulinism. The trial's failure has cast significant doubt on the future of the drug, which was being evaluated for a rare disease that causes low blood sugar.